Please Wait...

3 Reasons to Share Data from Unsuccessful Clinical Trials

3 Reasons to Share Data from Unsuccessful Clinical Trials

A recent proposal by the U.S. Department of Health and Human Services (HHS) could expand the amount of clinical trial data that drug companies must share with the public. Under the proposal, clinical trial sponsors would be required to report findings for drugs and devices that fail to reach approval.
 

Launched in 2000, ClinicalTrials.gov houses registration data for all trials regulated by the FDA, currently numbering more than 175,000 trials. Current regulations require drug companies to submit summary results (number of participants, age and gender, outcomes, and adverse events) within 1 year of trial completion for drugs and devices which receive approval. Under the new rule proposed by HHS, companies will also be required to report results for unapproved products, adding a significant amount of publicly available data to the site. Phase I trials, designed to test the safety of a drug or medical device do not fall under the provisions of the proposal. However, the NIH also plans to put in place a rule that requires submission to ClinicalTrials.gov results from all clinical trials that it funds, no matter how early or small.
 

Sharing Clinical Trial Data for Unapproved Compounds: Why the Change?

A recent analysis of 400 U.S. clinical trials found that even four years after the trials had been completed, nearly 30% had failed to share results by publishing in a scientific journal or reporting in ClinicalTrials.gov 1. Furthermore, negative clinical trial results are far less likely to make it into the scientific literature compared to positive results. Nonetheless, these data encompass a large number of studies and are important to clinicians, scientific research, and the general public.
 

Here are three reasons you should care about negative results from a clinical trial:
 

  1. Sharing Negative Results is Useful for Scientific Research
    When it comes to clinical trials (and scientific research), transparency with data helps researchers avoid duplicating failed trials. This directly reduces the risk for clinical trial participants, who are entrusting their health and well-being to the trial process. Negative results also help guide future research and the design and implementation of improved trials, eliminating redundant scientific work for which an answer already exists (just not in a published form). 
     

  2. Sharing Negative Results Helps Fulfill Society’s Ethical Responsibility to People Who Volunteer for Trials
    The clinical trial process (and thus approval of all drugs) relies on the voluntary participation of human subjects. Often times, participants join a trial not just for the potential benefit of personal treatment, but also for the possibility of improving the lives of others down the road. Sharing clinical trial data helps to maximize the potential benefit of each trial and helps to justify the participation of each human subject who has donated their time and efforts to the clinical trial process.
     

  3. Increase in Public Trust
    An increase in the transparency of clinical trial data will help foster an increase in trust between the general public and drug developers. Sharing clinical trial data with the worldwide scientific community in an open and efficient manner will also increase trust between the American taxpayers and the National Institutes of Health (NIH), who use their funds to help sponsor many clinical trials.


The HHS and the NIH are taking public comment on the two proposed policies until February of next year. It will be interesting to see the responses to this proposed change in reporting clinical trial data. What do you think?
 

1 Saito H and Gill CJ. PloS One. 2014 Jul 15; 9(7).

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Live from Las Vegas where Bioclinica's Research Development Director Marieke Cajal, PhD, is presenting on site star… https://t.co/lVglg6NWdV
bioclinica (7 minutes ago)
Many thanks all who attended @bioclinica's Executive Roundtable on Safety Mgmt for Pharma Cos in Japan in Tokyo th… https://t.co/OzHeSvHTUk
bioclinica (22 minutes ago)
RT @bioclinica: @CardiacSafety Consortium needs your feedback! Help make the upcoming think tank "Evaluation of #MobileTechnologies in #CV…
bioclinica (2 hours ago)
@CardiacSafety Consortium needs your feedback! Help make the upcoming think tank "Evaluation of… https://t.co/0Oc3z6zkO8
bioclinica (2 hours ago)
RT @CDISC: Special thanks to CDISC Member @bioclinica for hosting CDISC Public Training in Audubon, PA 2-6 Apr 2018. Register today. https:…
bioclinica (2 hours ago)
Bioclinica Delivers Individual Case Safety Report (ICSR) Processing w Quality & Consistency While Crossing One Mil… https://t.co/77NOME2Dj7
bioclinica (Yesterday)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen